Mariner
RLAY icon

Mariner’s Relay Therapeutics RLAY Stock Holding History

Mariner’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36,096
Closed -$358K – 3856
2026
Q1 		$358K Buy
+36,096
New +$323K ﹤0.01% 2719
2025
Q4 		– Sell
-27,756
Closed -$145K – 3763
2025
Q3 		$145K Buy
27,756
+14,094
+103% +$53.7K ﹤0.01% 3286
2025
Q2 		$47.3K Buy
+13,662
New +$40.6K ﹤0.01% 3356

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Mariner's RLAY Position: Q2 2026 in Review

Mariner sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 36,096 shares — an estimated $358K sold.

Mariner first reported a position in RLAY in Q2 2025 and held it in 3 quarters. The position peaked at $358K in Q1 2026. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Mariner reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mariner sold 36,096 Relay Therapeutics shares in Q2 2026, an estimated $358K.
  • Mariner first reported a position in Relay Therapeutics in Q2 2025 and held it in 3 quarters.
  • Mariner's Relay Therapeutics position peaked at $358K in Q1 2026.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.